Central nervous system characterization of the new cholecystokininB antagonist LY288513

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 3, 1996, Pages 493-502

  Helton, David R ^a   Berger, James E ^b   Czachura, Janet F ^a   Rasmussen, Kurt ^a   Kallman, Mary J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BUTLER UNIVERSITY   (United States)

Author keywords

Antianxiety; Antipsychotic; Behavior; CCK; Convulsions; Dopamine; Electrophysiology; LY262691; Schizophrenia; Substantia nigra; Ventral tegmentum

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DIAZEPAM; HEXOBARBITAL; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NEUROLEPTIC AGENT; PENTETRAZOLE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG POTENTIATION; ELECTROPHYSIOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOTOR COORDINATION; MOUSE; MUSCLE TONE; NEUROMUSCULAR FUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; SENSORIMOTOR FUNCTION; SUBSTANTIA NIGRA; TRANQUILIZING ACTIVITY; VENTRAL TEGMENTUM;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; HORMONE ANTAGONISTS; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; TIME FACTORS;

ANIMALIA;

EID: 0030005171     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02122-1     Document Type: Article

References (44)

1. 4 and panic. Arch. Gen. Psychiatry 47:395; 1990.
2. B antagonists LY262691, LY262684, and LY247348 on punished responding of squirrel monkeys. Soc. Neurosci. Abstr. 17:1063; 1991.
3. Beglinger, C.; Dill, S.; Meyer, B.; Werth, B. Treatment of biliary colic with loxiglumide. Lancet 2:167; 1989.
4. Bradwejn, J.; Koszycki, D.; Shriqui, C.; Meterissian, G. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry 35:83-85; 1990.
5. Bunney, B. S.; Grace, A. A. Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci. 23:1715-1728; 1978.
6. 10 midbrain dopaminergic neurons. J. Neurosci. 3:1607-1619; 1983.
7. Dantzer, R. Behavioral effects of benzodiazepines: A review. Biobehavioral. Rev. 1:71-86; 1977.
8. Davis, M. The mammalian startle response. In: Eaton, R. C., ed. Neural mechanisms of startle behavior. New York: Plenum Press; 1984: 287.
9. De Montigny, C. Cholecystokinin terapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry 46:511-517; 1989.
10. Dethloff, L. A.; De La Iglesia, F. A. Cholecystokinin antagonists: A toxicologie perspective. Drug Metab. Rev. 24(2):267-293; 1992.
11. Dohrenwend, B. P.; Egri, G. Recent stressful life events and episodes of schizophrenia. Schizophr. Bull. 7:12-23; 1981.
12. B receptor antagonist L-365-260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176:35-44; 1990.
13. Faris, P. L.; Komisaruk, B. R.; Watkins, L. R.; Amyer, D. J. Evidence of the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219:310-312; 1983.
14. Gaudreau, P.; Lavigne, G. J.; Quirion, R. Cholecystokinin antagonists proglumide, lorglumide and benzotript, but not L-364,718, interact with brain opioid binding sites. Neuropeptides 16:51-55; 1990.
15. Greenblatt, D.; Shader, R. Dependence, tolerance, and addiction to benzodiazepines: Clinical and pharmacokinetic considerations. Drug Metab. Rev. 8(1):13-28; 1978.
16. Hughes, J.; Woodruff, G. N. Neuropeptides: Function and clinical applications. Arzneim. Forsch./Drug Res. 42:250; 1992.
17. Innis, R. B.; Synder, S. H. Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA 77:6917-6921; 1980.
18. Irwin, S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiological state of the mouse. Psychpharmacologia (Berlin) 13: 222-257; 1968.
19. Kaneyuki, H.; Yokoo, H.; Tsuda, A.; Yoshida, M.; Mizuki, Y.; Yamada, M.; Tanaka, M. Psychological stress increases dopamine turnover selectively in mesoprefrontal dopamine neurons of rats: Reversal by diazepam. Brain Res. 557:154-161; 1991.
20. Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacol. 92:180-185; 1987.
21. Losonczy, M. F.; Davidson, M.; Davis, K. L. The dopamine hypothesis of schizophrenia. In: Meltzer, H. Y., ed. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:715-726.
22. Meyer, O. A.; Tilson, H. A.; Byrd, W. C.; Riley, M. T. A method for the routine assessment of fore-and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1:233-236; 1979.
23. Moran, T. H.; Robinson, P. H.; Goldrich, M. S.; Mchugh, P. R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362:175; 1986.
24. Olsen, R. W. Drug interactions at the GABA receptor-ionphore complex. Annu. Rev. Pharmacol. Toxicol. 22:245-277; 1982.
25. B receptors by L-365,260 induces analgesia in the squirrel monkey. Brain Res. 534:287-290; 1990.
26. Palmour, R.; Ervin, F. R.; Bradwein, J.; Howbert, J. J. Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCKB antagonist LY262691. Soc. Neurosci. Abstr. 17:1602; 1991.
27. B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19:75-78; 1991.
28. B antagonist LY262691 decreases midbrain dopamine unit activity. Eur. J. Pharmacol. 209:135-138; 1991.
29. B and cholecystokininA antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 264:480-488; 1993.
30. B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. Neuroreport 5:154-156; 1993.
31. Rataud, J.; Darche, F.; Piot, F. O.; Stutzmann, J. M.; Bohme, G. A.; Blanchard, J. C. Anxiolytic effect of CCK-antagonists on plus-maze behavior in mice. Brain Res. 548:315-317; 1991.
32. Roth, R. H.; Tam, S. Y; Ida, Y.; Yang, J. X.; Deutch, A. Y. Stress and the mesocorticolimbic dopamine systems. Ann. NY Acad. Sci. 537:138-147; 1988.
33. SAS Institute, Inc. (1985). The GLM Procedure. SAS User's Guide: Statistics, Version 5:433-506; 1985.
34. Siegmund, E.; Cadmus, R.; Lu, G. A method for evaluating both nonnarcotic and narcotic analgesics. Proc. Soc. Exp. Biol. Med. 95:729-731; 1957.
35. Silverman, M. A.; Greenberg, R. E.; Bank, S. Cholecystokinin receptor antagonists: A review. Am. J. Gastroenterol, 82(8):703-708; 1987.
36. B receptor antagonist. Br. J. Pharmacol. 104:239-245; 1991.
37. Singh, L.; Field, M. J.; Vass, C. A.; Hughes, J.; Woodruff, G. N. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. Br. J. Pharmacol. 105:8-10; 1992.
38. Spring, B. Stress and schizophrenia: some definitional issues. Schizophrenia Bull. 7:24-33; 1981.
39. Swinyard, E. A.; Brown, W. C.; Goodman, L. S. Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. 106:319-330; 1952.
40. 3 antagonists and benzodiazepines: Their comparative behavioral pharmacology. Chichester: Wiley; 1991:107-131.
41. Vaccarino, F. J. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors. Neurosci. Biobehav. Rev. 18:207-214; 1994.
42. 10 dopamine neurons. Science 221:1054-1057; 1983.
43. Wisenfeld-Hallin, X.; Xu, X.-J.; Hughes, J.; Horwell, D. C.; Hokfelt, T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Nat. Acad. Sci. USA 87:7105-7109; 1990.
44. Woods, J. H.; Katz, J. L.; Winger, G. Abuse liability of benzodiazepines. Pharmacol. Rev. 39(4):251-414; 1987.